Welcome to our dedicated page for IceCure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical Ltd. (Nasdaq: ICCM) has priced its public offering of 8,787,880 ordinary shares at $1.65 each, aiming to raise approximately $14.5 million before expenses. The funds will be utilized for developing next-generation systems, clinical data collection, regulatory approvals, marketing, and general corporate purposes. The offering is expected to close on December 23, 2022, pending customary conditions. A.G.P./Alliance Global Partners serves as the lead placement agent.
IceCure Medical Ltd. (Nasdaq: ICCM) announced a public offering of its ordinary shares, with all securities offered by the Company. The offering's completion is subject to market conditions, and details regarding size and terms are uncertain. Proceeds will fund the development of next-gen systems, clinical data collection, and regulatory approvals, among other uses. A.G.P./Alliance Global Partners is the lead placement agent. This offering is made under an effective shelf registration statement filed with the SEC.
IceCure Medical Ltd. (Nasdaq: ICCM) announced interim results from the ICESECRET study, presented at the Urological Association Conference in Eilat, Israel. The ProSense system effectively treats renal lesions under 5 cm in patients unfit for kidney-preserving surgery. Out of 115 enrolled patients, an 89.5% recurrence-free rate was observed for lesions ≤3 cm. The study reported 5 serious adverse events, with the majority being mild and resolved quickly. ProSense is approved in the U.S. and Europe for treating both benign and malignant kidney tumors.
IceCure Medical Ltd. (Nasdaq: ICCM) announced the promotion of Galit Bar Malik to VP of Operations and Service and the appointment of Vincent Chun Hung Chan as an independent director. Chan, a seasoned private equity executive with over 30 years of experience, brings a strong background in managing investment projects and corporate governance. This strategic addition aims to bolster operations in light of anticipated sales growth for the ProSense® system, which treats tumors through cryoablation technology. The company is focusing on launching ProSense in key markets, including Asia.
IceCure Medical (Nasdaq: ICCM) reported a 22% revenue decline to $2.1 million for the nine months ending September 30, 2022, but noted a positive sales increase of 65% in the U.S. and 37% in Europe. Key developments include the FDA filing for ProSense cryoablation for breast cancer and achieving Medicare coverage with a CPT Category III code effective January 1, 2023. Operating expenses rose to $13.8 million, leading to a net loss of $13 million. The company has $14.2 million in cash as of September 30, 2022. A conference call discussing these results is scheduled for December 5, 2022.
Summary not available.
IceCure Medical Ltd (NASDAQ: ICCM) will announce its financial results for the nine months ending September 30, 2022, on December 5, 2022, at 7:00 a.m. EST. A conference call will follow at 8:00 a.m. EST, featuring Dr. Hania Bednarski, an expert in minimally-invasive cryoablation technology. The ProSense® System, developed by IceCure, is a cryoablation treatment for tumors, providing a non-surgical alternative. Dr. Bednarski has been actively training surgeons in this technology.
IceCure Medical (NASDAQ: ICCM) will announce its financial results for the nine months ending September 30, 2022, on December 5, 2022. The results will be shared via a press release at 7:30 a.m. EST, followed by a conference call at 8:00 a.m. EST featuring Dr. Hania Bednarski, a cryoablation specialist. IceCure's ProSense technology offers a non-invasive alternative for tumor treatment. The system is FDA-cleared and CE-marked in Europe, focusing on breast, kidney, bone, and lung cancers. Forward-looking statements regarding the company’s future performance will be included.
IceCure Medical (NASDAQ: ICCM) achieved a significant milestone with the Centers for Medicare & Medicaid Services (CMS) assigning its ProSense cryoablation procedure for breast cancer to a Medicare Payment Group, effective January 1, 2023. This is the first payment assignment for cryoablation of breast cancer, contingent upon FDA marketing authorization. The procedure, priced at approximately $3,400, aims to provide a cost-effective alternative to traditional surgery, potentially improving patient outcomes and healthcare economics. IceCure's CEO emphasized the importance of this step in advancing treatment options for early-stage breast cancer.
IceCure Medical Ltd (NASDAQ: ICCM) announced its initiatives for Breast Cancer Awareness Month, focusing on the ProSense® cryoablation system, which offers a minimally invasive, effective treatment option for early-stage low-risk breast cancer. The company has filed for FDA marketing authorization and expanded installation of ProSense in multiple countries including the US and Europe. Key activities included physician training webinars and demonstrations at international conferences, emphasizing the system's cosmetic benefits and patient empowerment.